BMO Capital Markets Analysts Give Pfizer (PFE) a $39.00 Price Target
Pfizer (NYSE:PFE) has been assigned a $39.00 target price by stock analysts at BMO Capital Markets in a report issued on Friday. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. BMO Capital Markets’ price target indicates a potential upside of 6.97% from the stock’s previous close.
Other research analysts also recently issued reports about the stock. Jefferies Group reaffirmed a “hold” rating and issued a $35.00 target price on shares of Pfizer in a research note on Friday, August 18th. Vetr downgraded shares of Pfizer from a “buy” rating to a “hold” rating and set a $35.71 target price on the stock. in a research note on Wednesday, September 13th. Sanford C. Bernstein set a $39.00 target price on shares of Pfizer and gave the stock a “buy” rating in a research note on Tuesday, September 19th. Morgan Stanley raised shares of Pfizer from an “equal weight” rating to an “overweight” rating and lifted their target price for the stock from $35.00 to $39.00 in a research note on Wednesday, September 20th. Finally, Zacks Investment Research raised shares of Pfizer from a “hold” rating to a “buy” rating and set a $40.00 target price on the stock in a research note on Tuesday, October 3rd. Two equities research analysts have rated the stock with a sell rating, six have issued a hold rating and thirteen have issued a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $38.77.
Shares of Pfizer (NYSE:PFE) traded down $0.18 on Friday, hitting $36.46. 14,786,900 shares of the stock were exchanged, compared to its average volume of 19,888,109. The company has a market cap of $221,680.00, a price-to-earnings ratio of 14.66, a price-to-earnings-growth ratio of 2.59 and a beta of 1.01. The company has a current ratio of 1.43, a quick ratio of 1.15 and a debt-to-equity ratio of 0.56. Pfizer has a 1 year low of $30.90 and a 1 year high of $36.89.
Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, October 31st. The biopharmaceutical company reported $0.67 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.65 by $0.02. The firm had revenue of $13.17 billion during the quarter, compared to analyst estimates of $13.17 billion. Pfizer had a net margin of 18.69% and a return on equity of 25.41%. The business’s quarterly revenue was up .9% on a year-over-year basis. During the same period in the previous year, the business posted $0.61 EPS. equities research analysts forecast that Pfizer will post 2.59 EPS for the current year.
In other news, insider Alexander R. Mackenzie sold 14,700 shares of the company’s stock in a transaction dated Wednesday, November 1st. The shares were sold at an average price of $35.30, for a total value of $518,910.00. Following the sale, the insider now directly owns 117,432 shares of the company’s stock, valued at approximately $4,145,349.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Alexander R. Mackenzie sold 7,350 shares of the company’s stock in a transaction dated Monday, October 2nd. The stock was sold at an average price of $35.65, for a total transaction of $262,027.50. Following the completion of the sale, the executive vice president now directly owns 117,432 shares in the company, valued at $4,186,450.80. The disclosure for this sale can be found here. 0.06% of the stock is currently owned by insiders.
Large investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its stake in Pfizer by 2.3% in the 2nd quarter. Vanguard Group Inc. now owns 418,639,111 shares of the biopharmaceutical company’s stock worth $14,062,088,000 after purchasing an additional 9,239,499 shares in the last quarter. Ameriprise Financial Inc. boosted its stake in Pfizer by 4.4% in the 3rd quarter. Ameriprise Financial Inc. now owns 59,844,024 shares of the biopharmaceutical company’s stock worth $2,136,189,000 after purchasing an additional 2,502,659 shares in the last quarter. Franklin Resources Inc. boosted its stake in Pfizer by 0.9% in the 2nd quarter. Franklin Resources Inc. now owns 46,167,213 shares of the biopharmaceutical company’s stock worth $1,550,754,000 after purchasing an additional 389,629 shares in the last quarter. Dimensional Fund Advisors LP boosted its stake in Pfizer by 4.8% in the 2nd quarter. Dimensional Fund Advisors LP now owns 44,286,544 shares of the biopharmaceutical company’s stock worth $1,487,617,000 after purchasing an additional 2,028,313 shares in the last quarter. Finally, Fisher Asset Management LLC boosted its stake in Pfizer by 3.2% in the 3rd quarter. Fisher Asset Management LLC now owns 35,120,799 shares of the biopharmaceutical company’s stock worth $1,253,813,000 after purchasing an additional 1,085,437 shares in the last quarter. 69.89% of the stock is currently owned by hedge funds and other institutional investors.
WARNING: “BMO Capital Markets Analysts Give Pfizer (PFE) a $39.00 Price Target” was first posted by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another website, it was illegally stolen and reposted in violation of US and international copyright laws. The legal version of this news story can be accessed at https://www.americanbankingnews.com/2017/12/15/bmo-capital-markets-analysts-give-pfizer-pfe-a-39-00-price-target.html.
Pfizer Company Profile
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.